AstraZeneca stock follows its core pipeline and US listing

By Christina Vaughn, Background & Management desk. Reviewed on July 7, 2026 at 8:04 a.m. ET.

AstraZeneca plc (ISIN GB0009895292) is a global biopharmaceutical company with a US-listed ADR on Nasdaq and a business built around oncology, biopharmaceuticals and rare disease medicines. For US investors, the Nasdaq listing and the company’s broad therapy mix remain the key market frame.

Business model first

AstraZeneca develops and sells prescription medicines across oncology, cardiovascular and renal, respiratory and immunology, and rare disease. That mix gives the group exposure to long-running treatment areas rather than a single product cycle.

US market angle

The stock's US trading access matters because many large-cap health care investors follow the ADR alongside the London primary listing. In that setup, attention usually centers on pipeline execution, launch momentum and the next regulated data readouts.

Core therapies

Tagrisso, Farxiga, Imfinzi, Lynparza and Enhertu sit among the company's best-known medicines, and oncology remains the single most visible commercial pillar. AstraZeneca has also pushed deeper into respiratory and immunology with inherited franchise strength from older specialist-drug lines.

Price context

As of July 7, 2026, AstraZeneca shares were not paired with a live price in the available results, so this article keeps the focus on business context rather than an unverified quote. The Nasdaq ADR still gives US investors direct access to the name.

Representative product

Farxiga is a prescription medicine used in type 2 diabetes, heart failure and chronic kidney disease, making it a useful example of AstraZeneca's approach to multi-indication drugs. That strategy helps the company spread commercial risk across more than one treatment line.

Listing and quote

AstraZeneca trades in the US through its Nasdaq ADR, with London remaining the primary listing venue. The article can only state the venue from the available input, not a live market price.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.